These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22015772)

  • 1. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.
    Purandare AV; McDevitt TM; Wan H; You D; Penhallow B; Han X; Vuppugalla R; Zhang Y; Ruepp SU; Trainor GL; Lombardo L; Pedicord D; Gottardis MM; Ross-Macdonald P; de Silva H; Hosbach J; Emanuel SL; Blat Y; Fitzpatrick E; Taylor TL; McIntyre KW; Michaud E; Mulligan C; Lee FY; Woolfson A; Lasho TL; Pardanani A; Tefferi A; Lorenzi MV
    Leukemia; 2012 Feb; 26(2):280-8. PubMed ID: 22015772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
    Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
    Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
    Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
    Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
    Pardanani A
    Leukemia; 2008 Jan; 22(1):23-30. PubMed ID: 17882282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
    Yu V; Pistillo J; Archibeque I; Han Lee J; Sun BC; Schenkel LB; Geuns-Meyer S; Liu L; Emkey R
    Exp Hematol; 2013 May; 41(5):491-500. PubMed ID: 23340136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
    Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
    Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
    Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
    Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
    Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
    J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
    Hart S; Goh KC; Novotny-Diermayr V; Hu CY; Hentze H; Tan YC; Madan B; Amalini C; Loh YK; Ong LC; William AD; Lee A; Poulsen A; Jayaraman R; Ong KH; Ethirajulu K; Dymock BW; Wood JW
    Leukemia; 2011 Nov; 25(11):1751-9. PubMed ID: 21691275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.
    Mace TA; Shakya R; Elnaggar O; Wilson K; Komar HM; Yang J; Pitarresi JR; Young GS; Ostrowski MC; Ludwig T; Bekaii-Saab T; Bloomston M; Lesinski GB
    Oncotarget; 2015 Dec; 6(42):44509-22. PubMed ID: 26575024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
    Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
    Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
    Zak M; Mendonca R; Balazs M; Barrett K; Bergeron P; Blair WS; Chang C; Deshmukh G; Devoss J; Dragovich PS; Eigenbrot C; Ghilardi N; Gibbons P; Gradl S; Hamman C; Hanan EJ; Harstad E; Hewitt PR; Hurley CA; Jin T; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Kulagowski JJ; Labadie S; Liao J; Liimatta M; Lin Z; Lupardus PJ; Maxey RJ; Murray JM; Pulk R; Rodriguez M; Savage S; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Xiao L; Xiao Y
    J Med Chem; 2012 Jul; 55(13):6176-93. PubMed ID: 22698084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
    Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
    Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
    J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.